2月5日,卫材株式会社与复宏汉霖联合宣布,双方已就抗PD-1抗体斯鲁利单抗在日本市场达成独家商业化协议,并签订联合独家开发与生产许可协议。根据协议条款,卫材将获得斯鲁利单抗在日本的独家商业化权利;复宏汉霖计划在日本开展围手术期胃癌的临床试验,并将担任该产品的上市许可持有人(Marketing Authorization Holder)。卫材将向复宏汉霖支付7500万美元的首付款,最高可达8001...
Source Link2月5日,卫材株式会社与复宏汉霖联合宣布,双方已就抗PD-1抗体斯鲁利单抗在日本市场达成独家商业化协议,并签订联合独家开发与生产许可协议。根据协议条款,卫材将获得斯鲁利单抗在日本的独家商业化权利;复宏汉霖计划在日本开展围手术期胃癌的临床试验,并将担任该产品的上市许可持有人(Marketing Authorization Holder)。卫材将向复宏汉霖支付7500万美元的首付款,最高可达8001...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.